Bert van der Vegt
Bert van der Vegt
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Verified email at umcg.nl - Homepage
Title
Cited by
Cited by
Year
Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase i feasibility study
LE Lamberts, M Koch, JS de Jong, ALL Adams, J Glatz, MEG Kranendonk, ...
Clinical Cancer Research 23 (11), 2730-2741, 2017
1232017
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment
K Delli, EA Haacke, FGM Kroese, RP Pollard, S Ihrler, B van der Vegt, ...
Annals of the rheumatic diseases 75 (11), 1933-1938, 2016
652016
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
SQ Qiu, SJH Waaijer, MC Zwager, EGE de Vries, B van der Vegt, ...
Cancer treatment reviews 70, 178-189, 2018
642018
Heart failure stimulates tumor growth by circulating factors
WC Meijers, M Maglione, SJL Bakker, R Oberhuber, LM Kieneker, ...
Circulation 138 (7), 678-691, 2018
632018
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma
B Van der Vegt, MAJ De Roos, JL Peterse, C Patriarca, J Hilkens, ...
Histopathology 51 (3), 322-335, 2007
612007
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma
H Hartog, HM Horlings, B van der Vegt, B Kreike, A Ajouaou, ...
Breast cancer research and treatment 129 (3), 725-736, 2011
602011
Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast
MA de Roos, B van der Vegt, J de Vries, J Wesseling, GH de Bock
Annals of surgical oncology 14 (7), 2097-2104, 2007
532007
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast
MA de Roos, GH de Bock, J de Vries, B van der Vegt, J Wesseling
Journal of Surgical Research 140 (1), 109-114, 2007
502007
Axillary recurrence after sentinel lymph node biopsy
B van der Vegt, MHE Doting, PL Jager, J Wesseling, J de Vries
European Journal of Surgical Oncology (EJSO) 30 (7), 715-720, 2004
492004
Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development
EA Haacke, B van der Vegt, A Vissink, FKL Spijkervet, H Bootsma, ...
Annals of the Rheumatic Diseases 76 (10), 1781-1784, 2017
462017
Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer
B Van Der Vegt, GH De Bock, J Bart, NG Zwartjes, J Wesseling
Modern Pathology 22 (7), 879-886, 2009
422009
Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement
T Koopman, HJ Buikema, H Hollema, GH de Bock, B van der Vegt
Breast cancer research and treatment 169 (1), 33-42, 2018
412018
B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome
GM Verstappen, FGM Kroese, PM Meiners, OB Corneth, MG Huitema, ...
The Journal of Rheumatology 44 (1), 49-58, 2017
382017
Threshold analysis and biodistribution of fluorescently labeled bevacizumab in human breast cancer
M Koch, JS de Jong, J Glatz, P Symvoulidis, LE Lamberts, ALL Adams, ...
Cancer research 77 (3), 623-631, 2017
322017
Detection of HPV-associated oropharyngeal tumours in a 16-year cohort: more than meets the eye
LJ Melchers, MF Mastik, BS Cameron, BAC Van Dijk, GH De Bock, ...
British journal of cancer 112 (8), 1349-1357, 2015
322015
Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers
M Koller, SQ Qiu, MD Linssen, L Jansen, W Kelder, J de Vries, I Kruithof, ...
Nature communications 9 (1), 1-11, 2018
292018
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets
HH Nienhuis, SBM Gaykema, H Timmer-Bosscha, M Jalving, ...
Pharmacology & therapeutics 147, 63-79, 2015
292015
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast
MAJ De Roos, B Van Der Vegt, JL Peterse, C Patriarca, J De Vries, ...
Histopathology 51 (2), 227-238, 2007
282007
Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges
B Van der Vegt, GH de Bock, H Hollema, J Wesseling
Critical reviews in oncology/hematology 70 (1), 1-11, 2009
252009
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
F Bensch, AH Brouwers, MN Lub-de Hooge, JR de Jong, B van der Vegt, ...
European journal of nuclear medicine and molecular imaging 45 (13), 2300-2306, 2018
242018
The system can't perform the operation now. Try again later.
Articles 1–20